New combo therapy aims to boost leukemia treatment
NCT ID NCT05342584
First seen Jan 09, 2026 · Last updated Jun 09, 2026 · Updated 21 times
Summary
This early-phase study tests whether adding the drug venetoclax to standard chemotherapy is safe and effective for adults with newly diagnosed acute myeloid leukemia (AML) or advanced myelodysplastic syndrome (MDS). About 99 participants will receive different doses of venetoclax alongside chemo to find the best dose with the fewest side effects. The goal is to improve treatment outcomes for these aggressive blood cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Montefiore Einstein Cancer Center and Children's Hospital at Montefiore (CHAM)
RECRUITINGThe Bronx, New York, 10467, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.